Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

@inproceedings{Isenberg2015EfficacyAS,
  title={Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)},
  author={David Isenberg David Isenberg and Caroline Gordon and Daiana Licu and Samuel Copt and Claudia Rossi and David Wofsy and Alejandra M Babini and Mart{\'i}n L{\'a}zaro and Eleonora Lucero and C Merono and Oscar Luis Rillo and Alberto Spindler and Guillermo Tate and B Velasco Zamora and David Bossingham and Geoff Littlejohn and Dave Nicholls and Gloria M. Reeves and Maureen Rischmueller and Omid Zamani and Eri Sato and Morton Aaron Scheinberg and Cristiano Zerbini and Rasho K. Rashkov and Marija Glasnovi{\'c} and Du{\vs}anka Martinovi{\'c}-Kaliterna and Jadranka Morovi{\'c}-Vergles and Srdan Novak and Dana Tegzov{\'a} and Pavla Vavrincov{\'a} and Zahir Amoura and Paul Carle and {\'E}ric Hachulla and Christian Jorgensen and Jean Sibilia and J‐F. Viallard and J{\"u}rgen Braun and Falk Hiepe and Annegret Kuhn and H. G. Lorenz and Reinhold Schmidt and Hendrik Schulze-Koops and Jochen Wacker and Loukas Settas and S Chandra Mouli Veeravalli and Alexandra Balbir-Gurman and Pnina Langevitz and Dror Mevorach and Yair Molad and S -C Bae and Cs Cho and Hy Sook Kim and Chang Hee Suh and Daina Andersone and Nelly Raymond Ziade and Asta Baranauskaite and Sigita Stropuvienė and Sc Gun and N. Kong and Wahinnuddin Sulaiman and C Ramos Remus and C Saldate Alonso and Tom W. J. Huizinga and P Tak and Pieter van Paassen and Cesar Arroyo and Henry G{\'o}mez and Eul{\`a}lia P{\'e}rez and Edgar Ramiterre and Eduardo Salido and Marek Brzosko and Dariusz Chudzik and Andrzej Dyczek and Slawomir Jeka and Stanislaw Sierakowski and Zbigniew Zdrojewski and Olga Barbarash and Olga Ershova and A. S. Gordienko and N I Lomareva and Yu. B. Shvarts and V Sorotskaya and N. N. Vezikova and Sergey Yakushin and Mirjana Bogi{\'c} and Aleksandar Dimi{\'c} and Nemanja N Damjanov and Radmila R. Petrovic and Ljudmila Stojanovi{\'c} and Aditi Kalla and Ingrid Louw and Sauithree Nayiager and Hannes Reuter and Cathy Spargo and David A. Whitelaw and Jordi Carbonell Abell{\'o} and Antonio Fern{\'a}ndez Nebro and Juan Jes{\'u}s G{\'o}mez Reino and Francisco Javier L{\'o}pez Longo and Johannes von Kempis and C. Huang and JL Lan and H Lin and LB Liou and Ian Bruce and Hasan Tahir and Orest Abrahamovych and Oleksandr Dyadyk and Y Nikirenkov and Y Rudyk and Svitlana Smiyan and Mykola Stanislavchuk and S Ter-Vartanyan and Cynthia Aranow and Anca Dinu Askanase and Eliza Chakravarty and W. Winn Chatham and Molly P Clark and Patricia Dhar and Ara H Dikranian and J. Fiechtner and E M Ginzler and Cathi Harmon and W Knibbe and Eric S. Lee and Michael D. Lockshin and Michael Luggen and Elena M. Massarotti and Ghaith Mitri and Song-guo Peng and Nora G. Singer},
  booktitle={Annals of the rheumatic diseases},
  year={2015}
}
OBJECTIVES Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side effects. Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. METHODS In this double-blind, placebo-controlled study, patients with moderate-to-severe SLE were randomised to atacicept 75 mg or atacicept 150 mg administered subcutaneously, or placebo twice-weekly for 4 weeks, then… CONTINUE READING